Table 3.

Drugs impacting on hepcidin-mediated alteration of iron homeostasis.

Name(s)	Primary Indication(s)	Target	Drug Type	Mechanism
Tocilizumab	Rheumatoid arthritis Systemic juvenile idiopathic arthritis Giant cell arteritis MCD Cytokine release syndrome	IL6R	Humanized monoclonal antibody	IL6 signaling inhibition
Siltuximab	MCD	IL6	Chimeric monoclonal Antibody	IL6 binding
Infliximab	IBD (Crohn’s disease, Ulcerative colitis) Rheumatoid arthritis Psoriatic arthritis Ankylosing spondylitis Psoriasis	TNFα	Chimeric monoclonal antibody	TNFα binding/blocker
Adalimumab	IBD (Crohn’s disease, Ulcerative colitis) Rheumatoid arthritis Psoriatic arthritis Ankylosing spondylitis Psoriasis Hidradenitis suppurativa Juvenile idiopathic arthritis	TNFα	Humanized monoclonal antibody	TNFα binding/blocker
Momelotinib GS-0387 CYT-387	Myelofibrosis	JAK1 and JAK2	Small molecule	Jak1 and Jak2 inhibition Blockig of hepcidin production via ALK2 inhibition
CSJ137	Hepcidin modulation Anemia amelioration	BMP6	Antibody	BMP6 binding/blocking
SST0001 RO-82 RO-68 NAc-91 NAcRO-00	Myeloma therapy Hepcidin modulation	BMP6	Modified heparin	BMP6 binding
TP-0184	Antitumor activity in advanced solid tumors Hepcidin modulation Anemia amelioration	ALK2	Small molecule	ALK2 inhibition
h5F9.23, h5F9-AM8	Hepcidin modulation Anemia amelioration	HJV/RGMc	Antibody	BMP Co-receptor binding binding
Spiegelmer Aptamers NOX-H94H	Hepcidin modulation Anemia amelioration	Hepcidin	Lexaptepid pegol L-stereoisomeric RNA aptamer	Hepcidin binding
PRS-080	Hepcidin modulation Anemia amelioration	Hepcidin	Antichalin, bioengineered lipocalin	Hepcidin binding
Erythropoetin	Anemia	EpoR	Protein	Induction of Erythroferron and blockage of hepcidin